Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

61.99 +4.22 (+7.30%)
Streaming Delayed Price Updated: 2:39 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street
Is it too late to get on the bandwagon? 
Via The Motley Fool
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September
Results of the Resolve-AD trial with rezpegaldesleukin were better than expected. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?
Here's what needs to happen for these high flyers to continue soaring. 
Via The Motley Fool
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today
One of the company's pipeline drugs is showing significant promise. 
Via The Motley Fool
Why Is Nektar Therapeutics Stock Trading Lower On Thursday?
Nektar reported Phase 2b results showing rezpegaldesleukin improved eczema severity scores and met primary and key secondary endpoints in patients. 
Via Benzinga
Why Nektar Therapeutics Rippled Higher This Week
The company's competitive positioning might be stronger now, after disappointing results from a key rival. 
Via The Motley Fool
Topics Intellectual Property
What's Going On With Nektar Therapeutics Stock On Thursday?
Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Shoe Carnival, American Eagle, Ciena, Victoria's Secret And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Why Nektar Therapeutics Stock Popped 6% on Friday
The company said it has sufficient financial resources to fund its operations into early 2027. 
Via The Motley Fool
Nektar (NKTR) Q2 Revenue Falls 52%
Via The Motley Fool
3 Bullish Biotech Stocks With Explosive Growth Trends
These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies 
Via MarketBeat
Why Nektar Therapeutics Stock Dived by 3% Today
Via The Motley Fool
US Stock Futures Slip After Two Days Of Record Advances: 'FOMO Could Add Another 5%-10%...,' Says Expert
U.S. futures slipped on Tuesday after two days of record-setting advances. Futures of major benchmark indices were trading lower. 
Via Benzinga
MSC Industrial Direct, Constellation Brands And 3 Stocks To Watch Heading Into Tuesday
 
Via Benzinga
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories? 
Via MarketBeat
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead. 
Via MarketBeat
Nektar Nails Phase 2b Eczema Trial: BTIG Calls It A ‘Pound the Table BUY’, Wainwright Sees $120 Upside
The data showed strong efficacy across multiple endpoints and consistent safety, reinforcing confidence in rezpegaldesleukin’s potential as a differentiated treatment for atopic dermatitis. 
Via Stocktwits
Why Nektar Therapeutics Stock Was Red-Hot Today
Via The Motley Fool
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
AeroVironment Posts Better-Than-Expected Earnings, Joins QuantumScape, Bumble, BlackBerry And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Nektar Therapeutics Announces Positive Data From Eczema Drug In Mid-stage Trial: Stock More Than Doubles But Retail Sees It Rising Further
Nektar Therapeutics said its mid-stage trial showed that patients who received Rezpegaldesleukin demonstrated improvement in eczema area and severity score compared to placebo at week 16. 
Via Stocktwits
Topics Economy Government
Crude Oil Falls Sharply; US Current Account Deficit Widens In Q1
 
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.